The world is grappling with the far-reaching impacts of the COVID-19 pandemic and the HIV prevention field is no different. Most trials investigating new biomedical HIV prevention products have paused, citing concerns for the safety of trial participants and the study teams.
How COVID-19 is impacting research varies by trial and site, and efforts are ongoing to minimize impact on trial timelines and data. AVAC will continue to monitor developments—watch this space.
This document is to help advocates with links to the latest information about COVID-19, including information on its prevention, transmission, relationship to HIV and research that’s underway. Many of the links below are constantly updated so please click through for the latest.
PrEP introduction is gaining traction around the world. Check out AVAC’s graphic showing global totals, and the uptick in implementation studies, regulatory approvals, global recommendations and more.
We know that an AIDS vaccine is possible and that a vaccine will be an important part of a long-term strategy to end the AIDS epidemic. The road ahead is long, but clinical trials—even those with disappointing results—and early-stage research provide critical clues to the way forward. The graphics below represent key facts about the AIDS vaccine field.
Thursday, January 26, 2023
During this webinar, panelists unpacked the No Data No More manifesto and discussed preliminary findings from the TG scorecard, which looked at transgender representation in clinical trials over time. Speaker details, recording, and resources below.
Featured Leigh Ann van der Merwe — Founder and Director: Social, Health & Empowerment Feminist Collective of Transgender Women of Africa; Brian Minalga — AVAC consultant, Trans Inclusion Initiative; and Cindra Feuer — AVAC Senior Program Manager: Partnerships & Capacity Strengthening
AVAC submits comment and response to the United States Preventative Services Task Force (USPSTF) Draft Recommendation statement for PrEP. The USPSTF recommended an “A” Grade for PrEP that includes CAB for PrEP.
This is an updated introductory two-page document that describes HIV vaccines research and reviews key developments in the field.
Download the application here or click the link to the right of this page. Please note, you will need to download and fill the application on a laptop or desktop computer. It is not possible to use a mobile phone to fill out the application.
The Advocacy Navigator is an AVAC initiative combining training and mentorship to young and emerging advocates in the field of HIV prevention advocacy. The program involves three months of coursework and project development, followed by three months of “implementation” whereby Navigators implement all or a portion of their Community Advocacy Project plan with the support of their mentor. More information at www.avac.org/navigator.
This report provides a concise update on the full landscape of biomedical interventions: including PrEP products in the market and next-gen products in the pipeline—multipurpose products (MPTs), vaccines and broadly neutralizing antibodies.
This article from PLoS Global Public Health presents the results of an analysis examining whether policies enabling broad PrEP eligibility, HIV self-testing, and lowered age of consent to HIV testing and treatment services are correlated with PrEP uptake.